Gvoke HypoPen for Severe Hypoglycemia

Gvoke HypoPen is a prescription glucagon auto-injector used for emergency treatment of severe hypoglycemia in people with diabetes. It is an emergency rescue product, not a routine glucose-lowering treatment. Readers comparing diabetes medications can review King Pharmacy's broader Type 2 Diabetes Medication Options section separately from this rescue-medication page.

Product identity and current U.S. status

The current DailyMed label lists Gvoke under NDA 212097 and identifies Xeris Pharmaceuticals, Inc. as the packager and distributor. Gvoke HypoPen is a ready-to-use subcutaneous glucagon injection supplied as a single-dose auto-injector. The current label includes 0.5 mg and 1 mg HypoPen presentations.

The FDA-approved indication is treatment of severe hypoglycemia in adults and children age 2 years and older with diabetes. This distinction matters when researching the product: Gvoke is intended for an emergency in which severe low blood sugar requires assistance from another person. It should not be compared as though it were an alternative to routine medicines such as metformin, empagliflozin, or semaglutide.

What to compare before obtaining Gvoke

When checking a prescription or pharmacy listing, verify that the product is specifically Gvoke HypoPen, that the prescribed strength and presentation match the current label, and that the package is intact and within its labeled expiration period. Other glucagon products and other Gvoke presentations exist, so the brand name alone is not enough to identify the exact device.

Current availability can vary by pharmacy, wholesaler, prescribed presentation, and local supply. A page about Gvoke does not establish that King Pharmacy currently has a particular strength or package in stock. Confirm the exact prescribed product with a licensed pharmacy.

Price and insurance questions

Out-of-pocket cost can vary with insurance coverage, benefit design, deductible status, pharmacy pricing, and any manufacturer program for which a patient independently qualifies. Historical promotional offers should not be treated as current pricing. For a useful comparison, ask for the cost of the exact prescribed Gvoke presentation and whether the quoted amount reflects insurance, cash price, or a separate discount arrangement.

Safety and emergency context

Gvoke is an emergency prescription medicine. The current label instructs patients and caregivers to know the signs of severe hypoglycemia and to be familiar with the product's Instructions for Use before an emergency occurs. Important contraindications and warnings include certain pancreatic or adrenal tumors and serious hypersensitivity reactions. Product-specific instructions and emergency steps should come from the current FDA-approved labeling and the prescribing clinician, not from an old promotional page.

For routine Type 2 diabetes prescription research rather than emergency rescue information, return to Type 2 Diabetes Medication Options.